Baidu
map

2017年欧洲抗风湿病联盟对系统性硬化病治疗推荐意见的更新

2017-08-30 中华风湿病学杂志.2017,21(8):575-576. 发表于上海

2017 年EULAR 对2009 年EULAR 关于SSc 治疗的推荐意见进行了更新[1]。参与本次更新的工作小组包括32 位欧美的SSc 临床专家、2位欧洲硬皮病学会联盟(FESCA)推荐的患者、1 位临床流行病学专家以及2 位研究员。邀请欧洲硬皮病试验及研究组(EUSATR)所有研究成员组项目提交SSc 治疗相关的临床问题,并用Delphi 法进行选择。据此选出26 项不同干预措施共46 个

中文标题:

2017年欧洲抗风湿病联盟对系统性硬化病治疗推荐意见的更新

发布机构:

发布日期:

2017-08-30

简要介绍:

2017 年EULAR 对2009 年EULAR 关于SSc 治疗的推荐意见进行了更新[1]。参与本次更新的工作小组包括32 位欧美的SSc 临床专家、2位欧洲硬皮病学会联盟(FESCA)推荐的患者、1 位临床流行病学专家以及2 位研究员。邀请欧洲硬皮病试验及研究组(EUSATR)所有研究成员组项目提交SSc 治疗相关的临床问题,并用Delphi 法进行选择。据此选出26 项不同干预措施共46 个临床问题进行系统文献综述。新的推荐意见基于文献证据,且由临床专家及患者进行讨论。最终得到的16 条推荐意见(包括EULAR 2009 年的14 条推荐意见),主要涉及SSc 相关器官并发症、雷诺现象、肢端溃疡、肺动脉高压、皮肤及肺部疾病、肾危象及胃肠道受累的治疗。

译者: 北京大学人民医院风湿免疫科 姚海红,西藏自治区人民医院风湿血液科 白玛央金

拓展指南:系统性硬化相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017年欧洲抗风湿病联盟对系统性硬化病治疗推荐意见的更新)] GetToolGuiderByIdResponse(projectId=1, id=315e01c00150e0dd, title=2017年欧洲抗风湿病联盟对系统性硬化病治疗推荐意见的更新, enTitle=, guiderFrom=中华风湿病学杂志.2017,21(8):575-576., authorId=null, author=, summary=2017 年EULAR 对2009 年EULAR 关于SSc 治疗的推荐意见进行了更新[1]。参与本次更新的工作小组包括32 位欧美的SSc 临床专家、2位欧洲硬皮病学会联盟(FESCA)推荐的患者、1 位临床流行病学专家以及2 位研究员。邀请欧洲硬皮病试验及研究组(EUSATR)所有研究成员组项目提交SSc 治疗相关的临床问题,并用Delphi 法进行选择。据此选出26 项不同干预措施共46 个, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Aug 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017 年EULAR 对2009 年EULAR 关于SSc 治疗的推荐意见进行了更新[1]。参与本次更新的工作小组包括32 位欧美的SSc 临床专家、2位欧洲硬皮病学会联盟(FESCA)推荐的患者、1 位临床流行病学专家以及2 位研究员。邀请欧洲硬皮病试验及研究组(EUSATR)所有研究成员组项目提交SSc 治疗相关的临床问题,并用Delphi 法进行选择。据此选出26 项不同干预措施共46 个临床问题进行系统文献综述。新的推荐意见基于文献证据,且由临床专家及患者进行讨论。最终得到的16 条推荐意见(包括EULAR 2009 年的14 条推荐意见),主要涉及SSc 相关器官并发症、雷诺现象、肢端溃疡、肺动脉高压、皮肤及肺部疾病、肾危象及胃肠道受累的治疗。 </P>译者: 北京大学人民医院风湿免疫科 姚海红,西藏自治区人民医院风湿血液科 白玛央金 <P> </P>拓展指南:<strong>与<font color=red>系统性硬化</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=8932e1c001a4923c" title="2016年《BSR和BHPR系统性硬化症治疗指南》解读" target=_blank>2016年《BSR和BHPR系统性硬化症治疗指南》解读</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=5dfbe1c001a4029f" title="2017 EBMT建议:系统性硬化症患者进行造血干细胞移植的心肺评估" target=_blank>2017 EBMT建议:系统性硬化症患者进行造血干细胞移植的心肺评估</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=6e94d1c0013a33ae" title="2016 EULAR建议:系统性硬化的治疗(更新版)" target=_blank>2016 EULAR建议:系统性硬化的治疗(更新版)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=712551c00102562e" title="2013 ACR/EULAR 系统性硬化症分类标准" target=_blank>2013 ACR/EULAR 系统性硬化症分类标准</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=8fd261c00083254c" title="2011 系统性硬化病诊断及治疗指南" target=_blank>2011 系统性硬化病诊断及治疗指南</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E7%B3%BB%E7%BB%9F%E6%80%A7%E7%A1%AC%E5%8C%96" target=_blank>有关系统性硬化更多指南</a></ul>, tagList=[TagDto(tagId=11697, tagName=系统性硬化)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=21057, categoryName=梅斯医学-硬皮病网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5811, appHits=325, showAppHits=0, pcHits=4158, showPcHits=2104, likes=128, shares=12, comments=4, approvalStatus=1, publishedTime=Fri Oct 13 12:48:07 CST 2017, publishedTimeString=2017-08-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Oct 13 12:48:07 CST 2017, updatedBy=92910, updatedName=rayms, updatedTime=Thu Jan 04 02:36:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017年欧洲抗风湿病联盟对系统性硬化病治疗推荐意见的更新)])
2017年欧洲抗风湿病联盟对系统性硬化病治疗推荐意见的更新
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1051867, encodeId=4516105186e29, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:33:36 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999995, encodeId=164e99999573, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7da5550420, createdName=VinciLv, createdTime=Fri Jul 16 12:00:16 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918792, encodeId=12c5918e9243, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a94775031, createdName=1141938974, createdTime=Thu Jan 21 20:57:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252959, encodeId=17ed252959e8, content=好文章学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/01/a422505c84c5bd7df245dee314debefc.jpg, createdBy=31332101574, createdName=kalery, createdTime=Sun Oct 15 00:25:15 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    受益匪浅

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1051867, encodeId=4516105186e29, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:33:36 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999995, encodeId=164e99999573, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7da5550420, createdName=VinciLv, createdTime=Fri Jul 16 12:00:16 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918792, encodeId=12c5918e9243, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a94775031, createdName=1141938974, createdTime=Thu Jan 21 20:57:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252959, encodeId=17ed252959e8, content=好文章学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/01/a422505c84c5bd7df245dee314debefc.jpg, createdBy=31332101574, createdName=kalery, createdTime=Sun Oct 15 00:25:15 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2021-07-16 VinciLv

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1051867, encodeId=4516105186e29, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:33:36 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999995, encodeId=164e99999573, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7da5550420, createdName=VinciLv, createdTime=Fri Jul 16 12:00:16 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918792, encodeId=12c5918e9243, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a94775031, createdName=1141938974, createdTime=Thu Jan 21 20:57:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252959, encodeId=17ed252959e8, content=好文章学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/01/a422505c84c5bd7df245dee314debefc.jpg, createdBy=31332101574, createdName=kalery, createdTime=Sun Oct 15 00:25:15 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2021-01-21 1141938974

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1051867, encodeId=4516105186e29, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:33:36 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999995, encodeId=164e99999573, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7da5550420, createdName=VinciLv, createdTime=Fri Jul 16 12:00:16 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918792, encodeId=12c5918e9243, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a94775031, createdName=1141938974, createdTime=Thu Jan 21 20:57:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252959, encodeId=17ed252959e8, content=好文章学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/01/a422505c84c5bd7df245dee314debefc.jpg, createdBy=31332101574, createdName=kalery, createdTime=Sun Oct 15 00:25:15 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2017-10-15 kalery

    好文章学习了

    0

Baidu
map
Baidu
map
Baidu
map